Who are Encorafenib and Binimetinib's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Tunlametinib plus Vemurafenib.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/encorafenib-and-binimetinib.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Encorafenib and Binimetinib — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Encorafenib and Binimetinib (Encorafenib and Binimetinib) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: BRAF inhibitor + MEK inhibitor combination. Area: Oncology.

phase 3 BRAF inhibitor + MEK inhibitor combination BRAF V600E/K and MEK1/2 Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Encorafenib and Binimetinib (Encorafenib and Binimetinib) — Pierre Fabre Medicament. Encorafenib and binimetinib are a combination of a BRAF inhibitor and a MEK inhibitor that block the MAPK signaling pathway in BRAF-mutant melanoma cells.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Encorafenib and Binimetinib TARGET	Encorafenib and Binimetinib	Pierre Fabre Medicament	phase 3	BRAF inhibitor + MEK inhibitor combination	BRAF V600E/K and MEK1/2
Tunlametinib plus Vemurafenib	Tunlametinib plus Vemurafenib	Shanghai Kechow Pharma, Inc.	phase 3	BRAF inhibitor + MEK inhibitor combination	BRAF V600E and MEK1/2

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (BRAF inhibitor + MEK inhibitor combination class)

Pierre Fabre Medicament · 1 drug in this class
Shanghai Kechow Pharma, Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Encorafenib and Binimetinib — Competitive Intelligence Brief. https://druglandscape.com/ci/encorafenib-and-binimetinib. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab